Pamela  Vig net worth and biography

Pamela Vig Biography and Net Worth

Pamela Vig, Ph.D., is chief scientific officer for Mirum Pharmaceuticals, where she leads the scientific and clinical aspects of drug development and research, and medical affairs.

Pam has more than 25 years of industry experience in clinical development, medical affairs and translational science in various liver diseases including hepatitis B (HBV), hepatitis C (HCV), nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), and cholestatic liver disease, as well as HIV and other infectious diseases. Before joining Mirum, Pam held leadership roles at Allergan plc and Tobira Therapeutics as vice president of clinical research and discovery, as well as vice president of clinical research at Presidio Pharmaceuticals, Inc. Pam previously served as director, global medical affairs, at Johnson & Johnson in London, UK, and also held positions in clinical research and development at Idenix Pharmaceuticals and Gilead Sciences, Inc. Pam is a member of the PSC Forum Steering Committee as well as co-chair for the pediatric cholestatic disease working group under the Forum for Collaborative Research.

Pam holds a Ph.D. from Imperial College London in the departments of hepatology and histopathology.

What is Pamela Vig's net worth?

The estimated net worth of Pamela Vig is at least $1.25 million as of June 24th, 2024. Dr. Vig owns 27,406 shares of Mirum Pharmaceuticals stock worth more than $1,252,180 as of December 3rd. This net worth approximation does not reflect any other assets that Dr. Vig may own. Additionally, Dr. Vig receives a salary of $678,200.00 as Insider at Mirum Pharmaceuticals. Learn More about Pamela Vig's net worth.

How old is Pamela Vig?

Dr. Vig is currently 53 years old. There are 5 older executives and no younger executives at Mirum Pharmaceuticals. The oldest executive at Mirum Pharmaceuticals is Mr. Eric H. Bjerkholt M.B.A., Chief Financial Officer, who is 64 years old. Learn More on Pamela Vig's age.

What is Pamela Vig's salary?

As the Insider of Mirum Pharmaceuticals, Inc., Dr. Vig earns $678,200.00 per year. There are 2 executives that earn more than Dr. Vig. The highest earning executive at Mirum Pharmaceuticals is Mr. Christopher Peetz, Co-Founder, CEO and Director, who commands a salary of $1,310,000.00 per year. Learn More on Pamela Vig's salary.

How do I contact Pamela Vig?

The corporate mailing address for Dr. Vig and other Mirum Pharmaceuticals executives is 950 TOWER LANE SUITE 1050, FOSTER CITY CA, 94404. Mirum Pharmaceuticals can also be reached via phone at (650) 667-4085 and via email at [email protected]. Learn More on Pamela Vig's contact information.

Has Pamela Vig been buying or selling shares of Mirum Pharmaceuticals?

Pamela Vig has not been actively trading shares of Mirum Pharmaceuticals in the last ninety days. Most recently, Pamela Vig sold 30,559 shares of the business's stock in a transaction on Monday, June 24th. The shares were sold at an average price of $34.00, for a transaction totalling $1,039,006.00. Following the completion of the sale, the insider now directly owns 27,406 shares of the company's stock, valued at $931,804. Learn More on Pamela Vig's trading history.

Who are Mirum Pharmaceuticals' active insiders?

Mirum Pharmaceuticals' insider roster includes Ian Clements (CFO), James Flynn (Major Shareholder), Christopher Peetz (Co-Founder, CEO and Director), and Pamela Vig (Insider). Learn More on Mirum Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Mirum Pharmaceuticals?

During the last twelve months, Mirum Pharmaceuticals insiders bought shares 4 times. They purchased a total of 4,345 shares worth more than $115,064.40. During the last twelve months, insiders at the sold shares 11 times. They sold a total of 54,136 shares worth more than $1,738,025.44. The most recent insider tranaction occured on November, 14th when SVP Jolanda Howe sold 2,500 shares worth more than $117,750.00. Insiders at Mirum Pharmaceuticals own 22.9% of the company. Learn More about insider trades at Mirum Pharmaceuticals.

Information on this page was last updated on 11/14/2024.

Pamela Vig Insider Trading History at Mirum Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/24/2024Sell30,559$34.00$1,039,006.0027,406View SEC Filing Icon  
10/1/2021Sell1,364$19.26$26,270.64View SEC Filing Icon  
9/6/2019Buy1,612$10.97$17,683.64
See Full Table

Pamela Vig Buying and Selling Activity at Mirum Pharmaceuticals

This chart shows Pamela Vig's buying and selling at Mirum Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Mirum Pharmaceuticals Company Overview

Mirum Pharmaceuticals logo
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.
Read More

Today's Range

Now: $45.69
Low: $45.48
High: $46.73

50 Day Range

MA: $40.93
Low: $37.85
High: $46.65

2 Week Range

Now: $45.69
Low: $23.14
High: $48.89

Volume

35,429 shs

Average Volume

549,627 shs

Market Capitalization

$2.19 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.2